No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer

byTeddy Guo

January 7, 2021

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract Progression-Free Survival (PFS) was significantly longer with intensive chemotherapy in patients with advanced stage double or triple hit lymphoma (DHL, THL)

RelatedReports

Quick Take: Diffusion-weighted Imaging of Invasive Breast Cancer: Relationship to Distant Metastasis–free Survival

Oncology

Breast cancer screening with MRI provides modest benefit for high-risk women

March 2, 2026

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Oncology

Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer

January 28, 2026

Age and breast cancer risk factors associated with false-positive mammography results

Chronic Disease

The addition of a carboplatin to standard of care adjuvant chemotherapy improves survival outcomes in patients with high-risk, early-stage triple-negative breast cancer

January 12, 2026

Admission may not be needed following sleep apnea surgery

Weekly Rewinds

2 Minute Medicine Rewind December 29th, 2025

January 12, 2026

Glioblastoma phenotypes identified on MRI predict molecular behavior

Carboplatin as a potential adjunct therapy for recurrent high-grade glioma treatment

#VisualAbstract Fondazione Italiana Linfomi (FIL) Phase 3 trial: Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation (HSCT) in mantle cell lymphoma improves progression-free survival (PFS)

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

2 Minute Medicine Rewind January 11, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports